News

Recent News About Hesperos and Human-on-a-Chip Technology

FDA Modernization Act – An Open Letter to Congress

By Hesperos | September 7, 2022 | 0 Comments

Read the Open Letter here We are proud to support this open letter to congress encouraging representatives to pass the FDA Modernization Act.  Originally passed in 1938, the Federal Food, Drug, and Cosmetics Act (FFDCA) was … Read More

Financial Times publishes feature on the state of microphysiological systems, highlighting Hesperos

By Nate Post | August 15, 2022 | 0 Comments

Financial Times wrote an excellent feature on microphysiological systems, highlighting Hesperos’ Human-on-a-Chip.

Dr. Kronauge appointed as CEO

By Hesperos | May 26, 2022 | 0 Comments

Hesperos, Inc. appoints new Chief Executive Officer, Dr. James Kronauge I’m excited to join Hesperos as we expand the capabilities of the Human-on-Chip platform enabling drug developers unprecedented insight into specific disease states, especially for rare … Read More

Hesperos Shows Potential for In Vitro Approach to Replace Conventional Animal Efficacy Studies for Rare Neuromuscular Disorders

By Hesperos | April 19, 2022 | 0 Comments

1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.

2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.

Hesperos Validates Utility of Human-on-a-Chip® Approach to Model Rare Autoimmune Disease, Myasthenia Gravis

By Hesperos | November 22, 2021 | 0 Comments

Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More

Hesperos & Tabula Rasa Awarded $1.9M NIH Grant to investigate preventable Drug-induced Alzheimer’s Disease

By Hesperos | August 27, 2021 | 0 Comments

Hesperos and Tabula Rasa receive $1.9M National Institutes of Health Research Grant Focused on Preventable Drug-Induced Alzheimer’s Disease

Nature Scientific Reports Study Validates Utility of Human-on-a-Chip to Model NAFLD

By Hesperos | June 26, 2021 | 0 Comments

New study published in Nature Scientific Reports validates the utility of Human-on-a-Chip to model Nonalcoholic Fatty Liver Disease (NAFLD)